Promising Results for Alzheimer’s Treatment by Anavex Life Sciences
On September 15, 2023, groundbreaking data from a phase 2b/3 clinical trial revealed that the investigational medication blarcamesine, developed by Anavex Life Sciences, significantly reduces amyloid-ß biomarkers in patients with early Alzheimer’s disease. The findings were made public by Anavex Life Sciences, highlighting the potential of blarcamesine to alter the course of this debilitating condition. […]